These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35612283)

  • 1. Association between interferon-I producing plasmacytoid dendritic cells and thrombotic antiphospholipid syndrome.
    Rosa Dos Santos AP; de Oliveira Vaz C; Hounkpe BW; Jacintho BC; Oliveira JD; Tripiquia Vechiatto Mesquita GL; Pereira Dos Santos I; Annichino-Bizzacchi J; Appenzeller S; de Moraes Mazetto Fonseca B; Orsi FA
    Lupus; 2022 Aug; 31(9):1067-1077. PubMed ID: 35612283
    [No Abstract]   [Full Text] [Related]  

  • 2. Circulating plasmablasts contribute to antiphospholipid antibody production, associated with type I interferon upregulation.
    Hisada R; Kato M; Sugawara E; Kanda M; Fujieda Y; Oku K; Bohgaki T; Amengual O; Horita T; Yasuda S; Atsumi T
    J Thromb Haemost; 2019 Jul; 17(7):1134-1143. PubMed ID: 30864219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type I interferon pathway activation across the antiphospholipid syndrome spectrum: associations with disease subsets and systemic antiphospholipid syndrome presentation.
    Cecchi I; Radin M; Barinotti A; Foddai SG; Menegatti E; Roccatello D; Suárez A; Sciascia S; Rodríguez-Carrio J
    Front Immunol; 2024; 15():1351446. PubMed ID: 38550580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of clinical and serological features in thrombotic antiphospholipid syndrome patients, with and without associated systemic lupus erythematosus, followed for up to 42 years: A single centre retrospective study.
    Mittal P; Pacheco M; Trives-Folguera L; Rua J; Tohidi-Esfahani I; Cohen H; Efthymiou M; Isenberg D
    Lupus; 2024 Sep; 33(10):1082-1088. PubMed ID: 39092568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. microRNA downregulation in plasmacytoid dendritic cells in interferon-positive systemic lupus erythematosus and antiphospholipid syndrome.
    van den Hoogen LL; Rossato M; Lopes AP; Pandit A; Bekker CPJ; Fritsch-Stork RDE; van Roon JAG; Radstake TRDJ
    Rheumatology (Oxford); 2018 Sep; 57(9):1669-1674. PubMed ID: 29873766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Independent association of low IFNλ1 gene expression and type I IFN score/IFNλ1 ratio with obstetric manifestations and triple antiphospholipid antibody positivity in primary antiphospholipid syndrome.
    Flessa CM; Vlachiotis S; Nezos A; Andreakos E; Mavragani CP; Tektonidou MG
    Clin Immunol; 2019 Dec; 209():108265. PubMed ID: 31639447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disentangling the riddle of systemic lupus erythematosus with antiphospholipid syndrome: blood transcriptome analysis reveals a less-pronounced IFN-signature and distinct molecular profiles in venous versus arterial events.
    Nikolopoulos D; Loukogiannaki C; Sentis G; Garantziotis P; Manolakou T; Kapsala N; Nikoloudaki M; Pieta A; Flouda S; Parodis I; Bertsias G; Fanouriakis A; Filia A; Boumpas DT
    Ann Rheum Dis; 2024 Aug; 83(9):1132-1143. PubMed ID: 38609158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additional risk factors associated with thrombosis and pregnancy morbidity in a unique cohort of antiphospholipid antibody-positive patients.
    Li C; Zuo Y; Zhang S; Makris UE; Karp DR; Li Z
    Chin Med J (Engl); 2022 Mar; 135(6):658-664. PubMed ID: 35143425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical profiles and risk assessment in patients with antiphospholipid antibodies.
    Kato M; Hisada R; Atsumi T
    Expert Rev Clin Immunol; 2019 Jan; 15(1):73-81. PubMed ID: 30381978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying high-risk profile in primary antiphospholipid syndrome through cluster analysis: French multicentric cohort study.
    Guedon AF; Ricard L; Laurent C; De Moreuil C; Urbanski G; Deriaz S; Gerotziafas G; Elalamy I; Audemard A; Chasset F; Alamowitch S; Sellam J; Boffa JJ; Cohen A; Wahl C; Abisror N; Maillot F; Fain O; Mekinian A
    RMD Open; 2023 Mar; 9(1):. PubMed ID: 36894193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased eryptosis in patients with primary antiphospholipid syndrome (APS): a new actor in the pathogenesis of APS.
    Vomero M; Finucci A; Barbati C; Colasanti T; Ceccarelli F; Novelli L; Massaro L; Truglia S; Pensa C; Mauro FR; Foà R; Valesini G; Conti F; Alessandri C
    Clin Exp Rheumatol; 2021; 39(4):838-843. PubMed ID: 33124577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome.
    Tektonidou MG; Sotsiou F; Nakopoulou L; Vlachoyiannopoulos PG; Moutsopoulos HM
    Arthritis Rheum; 2004 Aug; 50(8):2569-79. PubMed ID: 15334471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood Cell-Bound C4d as a Marker of Complement Activation in Patients With the Antiphospholipid Syndrome.
    Lonati PA; Scavone M; Gerosa M; Borghi MO; Pregnolato F; Curreli D; Podda G; Femia EA; Barcellini W; Cattaneo M; Tedesco F; Meroni PL
    Front Immunol; 2019; 10():773. PubMed ID: 31031764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Systemic lupus erythematosus and antiphospholipid syndrome - diagnostic and therapeutic problems].
    Zdrojewski Z
    Wiad Lek; 2018; 71(1 pt 1):40-46. PubMed ID: 29558350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between non-thrombotic neurological and cardiac manifestations in patients with antiphospholipid syndrome.
    Stojanovich L; Kontic M; Smiljanic D; Djokovic A; Stamenkovic B; Marisavljevic D
    Clin Exp Rheumatol; 2013; 31(5):756-60. PubMed ID: 23899875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus.
    İlgen U; Yayla ME; Ateş A; Okatan İE; Yurteri EU; Torgutalp M; Keleşoğlu ABD; Turgay TM; Kınıklı G
    Lupus; 2018 Apr; 27(4):665-669. PubMed ID: 29050535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilizing type I interferon expression in the identification of antiphospholipid syndrome subsets.
    Cecchi I; Radin M; Rodríguez-Carrio J; Tambralli A; Knight JS; Sciascia S
    Expert Rev Clin Immunol; 2021 Apr; 17(4):395-406. PubMed ID: 33686921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of a gene signature related to thrombotic manifestations in antiphospholipid syndrome.
    Jacintho BC; Mazetto Fonseca BM; Hounkpe BW; Oliveira JD; Dos Santos APR; Vaz CO; de Paula EV; Orsi FA
    Front Med (Lausanne); 2023; 10():1139906. PubMed ID: 37035297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prevalence of antibodies to anionic phospholipids in patients with the primary antiphospholipid syndrome, systemic lupus erythematosus and their relatives and spouses.
    Radway-Bright EL; Ravirajan CT; Isenberg DA
    Rheumatology (Oxford); 2000 Apr; 39(4):427-31. PubMed ID: 10817777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of antiphospholipid antibody levels and type on thrombotic manifestations: results from the Serbian National Cohort Study.
    Stojanovich L; Markovic O; Marisavljevic D; Elezovic I; Ilijevski N; Stanisavljevic N
    Lupus; 2012 Mar; 21(3):338-45. PubMed ID: 21993381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.